Q1 Earnings Forecast for AC Immune Issued By HC Wainwright

AC Immune (NASDAQ:ACIU) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of AC Immune in a report issued on Thursday, November 5th. HC Wainwright analyst A. Ghosh forecasts that the company will post earnings per share of $0.06 for the quarter. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for AC Immune’s current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for AC Immune’s Q2 2027 earnings at $0.06 EPS, Q3 2027 earnings at $0.14 EPS and Q4 2027 earnings at $0.17 EPS.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $3.88 million for the quarter, compared to the consensus estimate of $1.62 million. AC Immune had a negative net margin of 181.38% and a negative return on equity of 97.79%.

ACIU has been the topic of a number of other reports. Weiss Ratings upgraded shares of AC Immune from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. BTIG Research restated a “buy” rating and set a $8.00 price target on shares of AC Immune in a research note on Wednesday, September 23rd. Finally, Zacks Research cut shares of AC Immune from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 28th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $7.50.

AC Immune Stock Performance

NASDAQ ACIU opened at $2.11 on Friday. AC Immune has a 52-week low of $2.02 and a 52-week high of $3.90. The company has a 50-day simple moving average of $2.55 and a 200 day simple moving average of $2.70. The company has a market capitalization of $214.73 million, a PE ratio of -4.22 and a beta of 1.64.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ACIU. AXQ Capital LP purchased a new stake in AC Immune in the 2nd quarter worth about $25,000. Dimensional Fund Advisors LP raised its stake in AC Immune by 82.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after acquiring an additional 176,701 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its stake in AC Immune by 8.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after acquiring an additional 30,035 shares during the period. Institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.